The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global PROteolysis Targeting Chimera (PROTAC) Market Research Report 2024

Global PROteolysis Targeting Chimera (PROTAC) Market Research Report 2024

Publishing Date : Feb, 2021

License Type :
 

Report Code : 1619856

No of Pages : 124

Synopsis
A proteolysis targeting chimera (PROTAC) is a heterobifunctional small molecule composed of two active domains and a linker capable of removing specific unwanted proteins. Rather than acting as a conventional enzyme inhibitor, a PROTAC works by inducing selective intracellular proteolysis. PROTACs consist of two covalently linked protein-binding molecules: one capable of engaging an E3 ubiquitin ligase, and another that binds to a target protein meant for degradation. Recruitment of the E3 ligase to the target protein results in ubiquitination and subsequent degradation of the target protein by the proteasome. Because PROTACs need only to bind their targets with high selectivity (rather than inhibit the target protein's enzymatic activity), there are currently many efforts to retool previously ineffective inhibitor molecules as PROTACs for next-generation drugs.

The global PROteolysis Targeting Chimera (PROTAC) market was valued at US$ XX million in 2019 and is expected to reach US$ XX million by the end of 2026, growing at a CAGR of XX% during 2021-2026.
This report focuses on PROteolysis Targeting Chimera (PROTAC) volume and value at the global level, regional level and company level. From a global perspective, this report represents overall PROteolysis Targeting Chimera (PROTAC) market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global PROteolysis Targeting Chimera (PROTAC) Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
ARV-110
ARV-471
KYM-001
Others

Segment by Application
Oncology
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

By Company
Arvinas
Kymera
C4 therapeutics
Captor therapeutics
Vividion
Cullgen
Pfizer
Merck
Genentech
AstraZeneca
Amgen
Bayer
Index
1 PROteolysis Targeting Chimera (PROTAC) Market Overview
1.1 Product Overview and Scope of PROteolysis Targeting Chimera (PROTAC)
1.2 PROteolysis Targeting Chimera (PROTAC) Segment by Type
1.2.1 Global PROteolysis Targeting Chimera (PROTAC) Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 ARV-110
1.2.3 ARV-471
1.2.4 KYM-001
1.2.5 Others
1.3 PROteolysis Targeting Chimera (PROTAC) Segment by Application
1.3.1 PROteolysis Targeting Chimera (PROTAC) Sales Comparison by Application: (2021-2027)
1.3.2 Oncology
1.3.3 Others
1.4 Global PROteolysis Targeting Chimera (PROTAC) Market Size Estimates and Forecasts
1.4.1 Global PROteolysis Targeting Chimera (PROTAC) Revenue 2016-2027
1.4.2 Global PROteolysis Targeting Chimera (PROTAC) Sales 2016-2027
1.4.3 PROteolysis Targeting Chimera (PROTAC) Market Size by Region: 2016 Versus 2021 Versus 2027

2 PROteolysis Targeting Chimera (PROTAC) Market Competition by Manufacturers
2.1 Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Manufacturers (2016-2021)
2.2 Global PROteolysis Targeting Chimera (PROTAC) Revenue Market Share by Manufacturers (2016-2021)
2.3 Global PROteolysis Targeting Chimera (PROTAC) Average Price by Manufacturers (2016-2021)
2.4 Manufacturers PROteolysis Targeting Chimera (PROTAC) Manufacturing Sites, Area Served, Product Type
2.5 PROteolysis Targeting Chimera (PROTAC) Market Competitive Situation and Trends
2.5.1 PROteolysis Targeting Chimera (PROTAC) Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest PROteolysis Targeting Chimera (PROTAC) Players Market Share by Revenue
2.5.3 Global PROteolysis Targeting Chimera (PROTAC) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 PROteolysis Targeting Chimera (PROTAC) Retrospective Market Scenario by Region
3.1 Global PROteolysis Targeting Chimera (PROTAC) Retrospective Market Scenario in Revenue by Region: 2016-2021
3.2 Global PROteolysis Targeting Chimera (PROTAC) Retrospective Market Scenario in Sales by Region: 2016-2021
3.3 North America PROteolysis Targeting Chimera (PROTAC) Market Facts & Figures by Country
3.3.1 North America PROteolysis Targeting Chimera (PROTAC) Sales by Country
3.3.2 North America PROteolysis Targeting Chimera (PROTAC) Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe PROteolysis Targeting Chimera (PROTAC) Market Facts & Figures by Country
3.4.1 Europe PROteolysis Targeting Chimera (PROTAC) Sales by Country
3.4.2 Europe PROteolysis Targeting Chimera (PROTAC) Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific PROteolysis Targeting Chimera (PROTAC) Market Facts & Figures by Region
3.5.1 Asia Pacific PROteolysis Targeting Chimera (PROTAC) Sales by Region
3.5.2 Asia Pacific PROteolysis Targeting Chimera (PROTAC) Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America PROteolysis Targeting Chimera (PROTAC) Market Facts & Figures by Country
3.6.1 Latin America PROteolysis Targeting Chimera (PROTAC) Sales by Country
3.6.2 Latin America PROteolysis Targeting Chimera (PROTAC) Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Market Facts & Figures by Country
3.7.1 Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Sales by Country
3.7.2 Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global PROteolysis Targeting Chimera (PROTAC) Historic Market Analysis by Type
4.1 Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Type (2016-2021)
4.2 Global PROteolysis Targeting Chimera (PROTAC) Revenue Market Share by Type (2016-2021)
4.3 Global PROteolysis Targeting Chimera (PROTAC) Price by Type (2016-2021)

5 Global PROteolysis Targeting Chimera (PROTAC) Historic Market Analysis by Application
5.1 Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Application (2016-2021)
5.2 Global PROteolysis Targeting Chimera (PROTAC) Revenue Market Share by Application (2016-2021)
5.3 Global PROteolysis Targeting Chimera (PROTAC) Price by Application (2016-2021)

6 Key Companies Profiled
6.1 Arvinas
6.1.1 Arvinas Corporation Information
6.1.2 Arvinas Description and Business Overview
6.1.3 Arvinas PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Arvinas Product Portfolio
6.1.5 Arvinas Recent Developments/Updates
6.2 Kymera
6.2.1 Kymera Corporation Information
6.2.2 Kymera Description and Business Overview
6.2.3 Kymera PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Kymera Product Portfolio
6.2.5 Kymera Recent Developments/Updates
6.3 C4 therapeutics
6.3.1 C4 therapeutics Corporation Information
6.3.2 C4 therapeutics Description and Business Overview
6.3.3 C4 therapeutics PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021)
6.3.4 C4 therapeutics Product Portfolio
6.3.5 C4 therapeutics Recent Developments/Updates
6.4 Captor therapeutics
6.4.1 Captor therapeutics Corporation Information
6.4.2 Captor therapeutics Description and Business Overview
6.4.3 Captor therapeutics PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Captor therapeutics Product Portfolio
6.4.5 Captor therapeutics Recent Developments/Updates
6.5 Vividion
6.5.1 Vividion Corporation Information
6.5.2 Vividion Description and Business Overview
6.5.3 Vividion PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Vividion Product Portfolio
6.5.5 Vividion Recent Developments/Updates
6.6 Cullgen
6.6.1 Cullgen Corporation Information
6.6.2 Cullgen Description and Business Overview
6.6.3 Cullgen PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Cullgen Product Portfolio
6.6.5 Cullgen Recent Developments/Updates
6.7 Pfizer
6.6.1 Pfizer Corporation Information
6.6.2 Pfizer Description and Business Overview
6.6.3 Pfizer PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Pfizer Product Portfolio
6.7.5 Pfizer Recent Developments/Updates
6.8 Merck
6.8.1 Merck Corporation Information
6.8.2 Merck Description and Business Overview
6.8.3 Merck PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021)
6.8.4 Merck Product Portfolio
6.8.5 Merck Recent Developments/Updates
6.9 Genentech
6.9.1 Genentech Corporation Information
6.9.2 Genentech Description and Business Overview
6.9.3 Genentech PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021)
6.9.4 Genentech Product Portfolio
6.9.5 Genentech Recent Developments/Updates
6.10 AstraZeneca
6.10.1 AstraZeneca Corporation Information
6.10.2 AstraZeneca Description and Business Overview
6.10.3 AstraZeneca PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021)
6.10.4 AstraZeneca Product Portfolio
6.10.5 AstraZeneca Recent Developments/Updates
6.11 Amgen
6.11.1 Amgen Corporation Information
6.11.2 Amgen PROteolysis Targeting Chimera (PROTAC) Description and Business Overview
6.11.3 Amgen PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021)
6.11.4 Amgen Product Portfolio
6.11.5 Amgen Recent Developments/Updates
6.12 Bayer
6.12.1 Bayer Corporation Information
6.12.2 Bayer PROteolysis Targeting Chimera (PROTAC) Description and Business Overview
6.12.3 Bayer PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021)
6.12.4 Bayer Product Portfolio
6.12.5 Bayer Recent Developments/Updates

7 PROteolysis Targeting Chimera (PROTAC) Manufacturing Cost Analysis
7.1 PROteolysis Targeting Chimera (PROTAC) Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of PROteolysis Targeting Chimera (PROTAC)
7.4 PROteolysis Targeting Chimera (PROTAC) Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 PROteolysis Targeting Chimera (PROTAC) Distributors List
8.3 PROteolysis Targeting Chimera (PROTAC) Customers

9 PROteolysis Targeting Chimera (PROTAC) Market Dynamics
9.1 PROteolysis Targeting Chimera (PROTAC) Industry Trends
9.2 PROteolysis Targeting Chimera (PROTAC) Growth Drivers
9.3 PROteolysis Targeting Chimera (PROTAC) Market Challenges
9.4 PROteolysis Targeting Chimera (PROTAC) Market Restraints

10 Global Market Forecast
10.1 PROteolysis Targeting Chimera (PROTAC) Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of PROteolysis Targeting Chimera (PROTAC) by Type (2022-2027)
10.1.2 Global Forecasted Revenue of PROteolysis Targeting Chimera (PROTAC) by Type (2022-2027)
10.2 PROteolysis Targeting Chimera (PROTAC) Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of PROteolysis Targeting Chimera (PROTAC) by Application (2022-2027)
10.2.2 Global Forecasted Revenue of PROteolysis Targeting Chimera (PROTAC) by Application (2022-2027)
10.3 PROteolysis Targeting Chimera (PROTAC) Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of PROteolysis Targeting Chimera (PROTAC) by Region (2022-2027)
10.3.2 Global Forecasted Revenue of PROteolysis Targeting Chimera (PROTAC) by Region (2022-2027)

11 Research Finding and Conclusion

12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
List of Tables
Table 1. Global PROteolysis Targeting Chimera (PROTAC) Sales (K Units) Growth Rate Comparison by Type (2021-2027)
Table 2. Global PROteolysis Targeting Chimera (PROTAC) Sales (K Units) Comparison by Application (2021-2027)
Table 3. Global PROteolysis Targeting Chimera (PROTAC) Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers PROteolysis Targeting Chimera (PROTAC) Covered in This Study
Table 5. Global PROteolysis Targeting Chimera (PROTAC) Sales (K Units) of Key Manufacturers (2016-2021)
Table 6. Global PROteolysis Targeting Chimera (PROTAC) Sales Share by Manufacturers (2016-2021)
Table 7. Global PROteolysis Targeting Chimera (PROTAC) Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global PROteolysis Targeting Chimera (PROTAC) Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market PROteolysis Targeting Chimera (PROTAC) Average Price (US$/Unit) of Key Manufacturers (2016-2021)
Table 10. Manufacturers PROteolysis Targeting Chimera (PROTAC) Manufacturing Sites and Area Served
Table 11. Manufacturers PROteolysis Targeting Chimera (PROTAC) Product Type
Table 12. Global PROteolysis Targeting Chimera (PROTAC) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global PROteolysis Targeting Chimera (PROTAC) by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in PROteolysis Targeting Chimera (PROTAC) as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global PROteolysis Targeting Chimera (PROTAC) Sales by Region (2016-2021) & (K Units)
Table 16. Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Region (2016-2021)
Table 17. Global PROteolysis Targeting Chimera (PROTAC) Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America PROteolysis Targeting Chimera (PROTAC) Sales by Country (2016-2021) & (K Units)
Table 19. North America PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Country (2016-2021)
Table 20. North America PROteolysis Targeting Chimera (PROTAC) Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America PROteolysis Targeting Chimera (PROTAC) Revenue Market Share by Country (2016-2021)
Table 22. Europe PROteolysis Targeting Chimera (PROTAC) Sales by Country (2016-2021) & (K Units)
Table 23. Europe PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Country (2016-2021)
Table 24. Europe PROteolysis Targeting Chimera (PROTAC) Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe PROteolysis Targeting Chimera (PROTAC) Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific PROteolysis Targeting Chimera (PROTAC) Sales by Region (2016-2021) & (K Units)
Table 27. Asia Pacific PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific PROteolysis Targeting Chimera (PROTAC) Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific PROteolysis Targeting Chimera (PROTAC) Revenue Market Share by Region (2016-2021)
Table 30. Latin America PROteolysis Targeting Chimera (PROTAC) Sales by Country (2016-2021) & (K Units)
Table 31. Latin America PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Country (2016-2021)
Table 32. Latin America PROteolysis Targeting Chimera (PROTAC) Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America PROteolysis Targeting Chimera (PROTAC) Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Sales by Country (2016-2021) & (K Units)
Table 35. Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Revenue Market Share by Country (2016-2021)
Table 38. Global PROteolysis Targeting Chimera (PROTAC) Sales (K Units) by Type (2016-2021)
Table 39. Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Type (2016-2021)
Table 40. Global PROteolysis Targeting Chimera (PROTAC) Revenue (Million US$) by Type (2016-2021)
Table 41. Global PROteolysis Targeting Chimera (PROTAC) Revenue Share by Type (2016-2021)
Table 42. Global PROteolysis Targeting Chimera (PROTAC) Price (US$/Unit) by Type (2016-2021)
Table 43. Global PROteolysis Targeting Chimera (PROTAC) Sales (K Units) by Application (2016-2021)
Table 44. Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Application (2016-2021)
Table 45. Global PROteolysis Targeting Chimera (PROTAC) Revenue (Million US$) by Application (2016-2021)
Table 46. Global PROteolysis Targeting Chimera (PROTAC) Revenue Share by Application (2016-2021)
Table 47. Global PROteolysis Targeting Chimera (PROTAC) Price (US$/Unit) by Application (2016-2021)
Table 48. Arvinas Corporation Information
Table 49. Arvinas Description and Business Overview
Table 50. Arvinas PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 51. Arvinas PROteolysis Targeting Chimera (PROTAC) Product
Table 52. Arvinas Recent Developments/Updates
Table 53. Kymera Corporation Information
Table 54. Kymera Description and Business Overview
Table 55. Kymera PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 56. Kymera PROteolysis Targeting Chimera (PROTAC) Product
Table 57. Kymera Recent Developments/Updates
Table 58. C4 therapeutics Corporation Information
Table 59. C4 therapeutics Description and Business Overview
Table 60. C4 therapeutics PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 61. C4 therapeutics PROteolysis Targeting Chimera (PROTAC) Product
Table 62. C4 therapeutics Recent Developments/Updates
Table 63. Captor therapeutics Corporation Information
Table 64. Captor therapeutics Description and Business Overview
Table 65. Captor therapeutics PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 66. Captor therapeutics PROteolysis Targeting Chimera (PROTAC) Product
Table 67. Captor therapeutics Recent Developments/Updates
Table 68. Vividion Corporation Information
Table 69. Vividion Description and Business Overview
Table 70. Vividion PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 71. Vividion PROteolysis Targeting Chimera (PROTAC) Product
Table 72. Vividion Recent Developments/Updates
Table 73. Cullgen Corporation Information
Table 74. Cullgen Description and Business Overview
Table 75. Cullgen PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 76. Cullgen PROteolysis Targeting Chimera (PROTAC) Product
Table 77. Cullgen Recent Developments/Updates
Table 78. Pfizer Corporation Information
Table 79. Pfizer Description and Business Overview
Table 80. Pfizer PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 81. Pfizer PROteolysis Targeting Chimera (PROTAC) Product
Table 82. Pfizer Recent Developments/Updates
Table 83. Merck Corporation Information
Table 84. Merck Description and Business Overview
Table 85. Merck PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 86. Merck PROteolysis Targeting Chimera (PROTAC) Product
Table 87. Merck Recent Developments/Updates
Table 88. Genentech Corporation Information
Table 89. Genentech Description and Business Overview
Table 90. Genentech PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 91. Genentech PROteolysis Targeting Chimera (PROTAC) Product
Table 92. Genentech Recent Developments/Updates
Table 93. AstraZeneca Corporation Information
Table 94. AstraZeneca Description and Business Overview
Table 95. AstraZeneca PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 96. AstraZeneca PROteolysis Targeting Chimera (PROTAC) Product
Table 97. AstraZeneca Recent Developments/Updates
Table 98. Amgen Corporation Information
Table 99. Amgen Description and Business Overview
Table 100. Amgen PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 101. Amgen PROteolysis Targeting Chimera (PROTAC) Product
Table 102. Amgen Recent Developments/Updates
Table 103. Bayer Corporation Information
Table 104. Bayer Description and Business Overview
Table 105. Bayer PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 106. Bayer PROteolysis Targeting Chimera (PROTAC) Product
Table 107. Bayer Recent Developments/Updates
Table 108. Production Base and Market Concentration Rate of Raw Material
Table 109. Key Suppliers of Raw Materials
Table 110. PROteolysis Targeting Chimera (PROTAC) Distributors List
Table 111. PROteolysis Targeting Chimera (PROTAC) Customers List
Table 112. PROteolysis Targeting Chimera (PROTAC) Market Trends
Table 113. PROteolysis Targeting Chimera (PROTAC) Growth Drivers
Table 114. PROteolysis Targeting Chimera (PROTAC) Market Restraints
Table 115. Global PROteolysis Targeting Chimera (PROTAC) Sales Forecast by Type (2022-2027) & (K Units)
Table 116. Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share Forecast by Type (2022-2027)
Table 117. Global PROteolysis Targeting Chimera (PROTAC) Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 118. Global PROteolysis Targeting Chimera (PROTAC) Revenue Market Share Forecast by Type (2022-2027)
Table 119. Global PROteolysis Targeting Chimera (PROTAC) Sales Forecast by Application (2022-2027) & (K Units)
Table 120. Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share Forecast by Application (2022-2027)
Table 121. Global PROteolysis Targeting Chimera (PROTAC) Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 122. Global PROteolysis Targeting Chimera (PROTAC) Revenue Market Share Forecast by Application (2022-2027)
Table 123. Global PROteolysis Targeting Chimera (PROTAC) Sales Forecast by Region (2022-2027) & (K Units)
Table 124. Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share Forecast by Region (2022-2027)
Table 125. Global PROteolysis Targeting Chimera (PROTAC) Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 126. Global PROteolysis Targeting Chimera (PROTAC) Revenue Market Share Forecast by Region (2022-2027)
Table 127. Research Programs/Design for This Report
Table 128. Key Data Information from Secondary Sources
Table 129. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of PROteolysis Targeting Chimera (PROTAC)
Figure 2. Global PROteolysis Targeting Chimera (PROTAC) Market Share by Type in 2020 & 2027
Figure 3. ARV-110 Product Picture
Figure 4. ARV-471 Product Picture
Figure 5. KYM-001 Product Picture
Figure 6. Others Product Picture
Figure 7. Global PROteolysis Targeting Chimera (PROTAC) Market Share by Application in 2020 & 2027
Figure 8. Oncology
Figure 9. Others
Figure 10. Global PROteolysis Targeting Chimera (PROTAC) Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global PROteolysis Targeting Chimera (PROTAC) Market Size 2016-2027 (US$ Million)
Figure 12. Global PROteolysis Targeting Chimera (PROTAC) Sales 2016-2027 (K Units)
Figure 13. Global PROteolysis Targeting Chimera (PROTAC) Market Size Market Share by Region: 2016 VS 20210 VS 2027
Figure 14. PROteolysis Targeting Chimera (PROTAC) Sales Share by Manufacturers in 2020
Figure 15. Global PROteolysis Targeting Chimera (PROTAC) Revenue Share by Manufacturers in 2020
Figure 16. The Global 5 and 10 Largest PROteolysis Targeting Chimera (PROTAC) Players: Market Share by Revenue in 2020
Figure 17. PROteolysis Targeting Chimera (PROTAC) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 18. Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Region (2016-2021)
Figure 19. Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Region in 2020
Figure 20. Global PROteolysis Targeting Chimera (PROTAC) Revenue Market Share by Region (2016-2021)
Figure 21. Global PROteolysis Targeting Chimera (PROTAC) Revenue Market Share by Region in 2020
Figure 22. U.S. PROteolysis Targeting Chimera (PROTAC) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 23. Canada PROteolysis Targeting Chimera (PROTAC) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 24. Germany PROteolysis Targeting Chimera (PROTAC) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 25. France PROteolysis Targeting Chimera (PROTAC) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 26. U.K. PROteolysis Targeting Chimera (PROTAC) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. Italy PROteolysis Targeting Chimera (PROTAC) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. Russia PROteolysis Targeting Chimera (PROTAC) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. China PROteolysis Targeting Chimera (PROTAC) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. Japan PROteolysis Targeting Chimera (PROTAC) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. South Korea PROteolysis Targeting Chimera (PROTAC) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. India PROteolysis Targeting Chimera (PROTAC) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. Australia PROteolysis Targeting Chimera (PROTAC) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. Taiwan PROteolysis Targeting Chimera (PROTAC) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. Indonesia PROteolysis Targeting Chimera (PROTAC) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Thailand PROteolysis Targeting Chimera (PROTAC) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Malaysia PROteolysis Targeting Chimera (PROTAC) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Philippines PROteolysis Targeting Chimera (PROTAC) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Vietnam PROteolysis Targeting Chimera (PROTAC) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Mexico PROteolysis Targeting Chimera (PROTAC) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Brazil PROteolysis Targeting Chimera (PROTAC) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Argentina PROteolysis Targeting Chimera (PROTAC) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Turkey PROteolysis Targeting Chimera (PROTAC) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Saudi Arabia PROteolysis Targeting Chimera (PROTAC) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. UAE PROteolysis Targeting Chimera (PROTAC) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 46. Sales Market Share of PROteolysis Targeting Chimera (PROTAC) by Type (2016-2021)
Figure 47. Sales Market Share of PROteolysis Targeting Chimera (PROTAC) by Application (2016-2021)
Figure 48. Sales Market Share of PROteolysis Targeting Chimera (PROTAC) by Application in 2020
Figure 49. Revenue Share of PROteolysis Targeting Chimera (PROTAC) by Application (2016-2021)
Figure 50. Revenue Share of PROteolysis Targeting Chimera (PROTAC) by Application in 2020
Figure 51. Manufacturing Cost Structure of PROteolysis Targeting Chimera (PROTAC)
Figure 52. Manufacturing Process Analysis of PROteolysis Targeting Chimera (PROTAC)
Figure 53. PROteolysis Targeting Chimera (PROTAC) Industrial Chain Analysis
Figure 54. Channels of Distribution
Figure 55. Distributors Profiles
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’